Skip to main content

Anthem Biosciences Ltd

Stage 2 · Advancing · week 20Setup 5.3 ★ FairStrong +5.9

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. More about the company

₹887.1
-0.37% today
₹49,827 Cr · Large cap
Market Neutral — FadingHealth Care 45.7% in Stage 2-1.4 pts / 20dBiotechnology 22.2%-22.2 pts
Loading price chart…
vs 52W High
-7.4%
₹592.4 lo₹957.8 hi
7.4% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 20
1w13w26w
Week 20 — proven structure, sweet spot
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
17.9%
200 DMA: ₹752.4 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.21x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -2.6% vs MA50 +6.4%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-5.0%
3M
+18.5%
6M
+33.6%
YTD
+32.5%
1Y
+15.8%
Sector
Health Care
↓ Peaking
Stage 2%
45.7%
20d Δ
-1.4pp
1M return
-1.8%
3M return
+4.4%
Sector Stage-2 % · last 20 days
This stock ranks #47 of 77 Stage 2 stocks in Health Care by RS.
Industry
Biotechnology
↓ Peaking
Stage 2%
22.2%
20d Δ
-22.2pp
1M return
-4.7%
3M return
+5.2%
Industry Stage-2 % · last 20 days
Ranks #2 of 2 Stage 2 stocks in this industry. Top tier.
Stage Cycle Timeline2025-07-21 → 2026-10-07
S? 42w
S2 20w
2025-07-212026-10-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w → S1 1w → S2 20w current
Total tracked: 63 weeks across 3 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-05-20
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-07S2
Wk 20 · Vol 0.21x
2026-10-06S2
Wk 20 · Vol 0.87x
2026-10-05S2
Wk 20 · Vol 0.37x
2026-10-01S2
Wk 20 · Vol 0.76x
2026-09-30S2
Wk 19 · Vol 0.22x
2026-09-29S2
Wk 19 · Vol 0.78x
2026-09-28S2
Wk 19 · Vol 0.55x
2026-09-25S2
Wk 19 · Vol 0.40x
2026-09-24S2
Wk 19 · Vol 0.43x
2026-09-23S2
Wk 18 · Vol 0.48x
2026-09-22S2
Wk 18 · Vol 0.53x
2026-09-21S2
Wk 18 · Vol 0.36x
Sector Peers — Stage 2All →
KOPRAN
wk 19 · -5.0% from hi
9.0
SMSPHARMA
wk 3 · -3.0% from hi
8.7
KILITCH
wk 2 · -1.7% from hi
8.7
BAFNAPH
wk 17 · 0.0% from hi
8.6
ZIMLAB
wk 21 · 0.0% from hi
8.3
Moving averages & range
50 DMA
₹883.9
200 DMA
₹752.4
52W High
₹957.8
52W Low
₹592.4
5D Low
₹851.9
Resistance levels (recent highs)
20d High
₹957.8
60d High
₹957.8
120d High
₹957.8
250d High
₹957.8
Next resistance
+8.0%
to 20d High
P/E (TTM)
72.6
Forward 48.3
Earnings Growth (YoY)
+127.2%
Revenue +26.4%
ROE
+21.7%
Profit margin +27.9%
Dividend Yield
0.26%
P/B 14.0
About this companyHealth Care· Biotechnology

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry. It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lactobacillus species, bifidobacterium species, streptococcus species and saccharomyces boulardii; enzymes; peptides, including semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide; nutritional actives, vitamin analogues, and APIs. The company was incorporated in 2006 and is based in Bengaluru, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.